Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01AAI
|
||||
| Former ID |
DIB021204
|
||||
| Drug Name |
VUF5574
|
||||
| Synonyms |
VUF 5574; VUF-5574
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H17N5O2
|
||||
| InChI |
InChI=1S/C21H17N5O2/c1-28-18-11-5-4-10-17(18)24-21(27)26-20-15-8-2-3-9-16(15)23-19(25-20)14-7-6-12-22-13-14/h2-13H,1H3,(H2,23,24,25,26,27)
|
||||
| InChIKey |
YRAFEJSZTVWUMD-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5950368, 9446063, 11111956, 14779586, 17405801, 24278772, 26753673, 35306473, 47425390, 50107192, 50107193, 50107194, 50159373, 53778353, 57356688, 85231283, 89077934, 92303145, 103269001, 103987390, 105296783, 112596066, 121364787, 124750354, 124881800, 124881801, 124881802, 129835621, 134964208, 135698538, 162250190, 163123911, 165358675, 178100321, 204356811, 227197517, 241182360, 252216598
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Antagonist | [2] | |
| Adenosine A1 receptor | Target Info | Antagonist | [3] | ||
| Adenosine A2b receptor | Target Info | Antagonist | [3] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholism | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3280). | ||||
| REF 2 | J Med Chem. 2000 Jun 1;43(11):2227-38.Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. | ||||
| REF 3 | J Med Chem. 1998 Oct 8;41(21):3987-93.A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.